Current issue
Journal content
Articles in press
Archive
About the Journal
About the Polish Annals of Medicine
Editorial Board
Abstracting & indexing
Open Access policy
Charges
Affiliated institutions
Contact
Instructions
Peer review process
Guide for authors
Publication ethics
Ethics and Patient Consent
User License
Usage of third party materials
Disclaimer
Statement on Artificial Intelligence
Reviewers
Guide for reviewers
Review Form
CASE REPORT
Plaque psoriasis and psoriatic arthritis associated with uveitis and cystoid macular edema treated with adalimumab: A case report and literature review
Waldemar Placek
1,2
1
Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, University of Warmia and Mazury in Olsztyn, Poland
2
Department of Rheumatology, Municipal Hospital in Olsztyn, Poland
3
Department of Ophthalmology, Municipal Hospital in Olsztyn, Poland
Submission date: 2016-10-03
Acceptance date: 2016-11-07
Online publication date: 2017-03-20
Publication date: 2020-03-22
Corresponding author
Agnieszka Owczarczyk-Saczonek
Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, University of Warmia and Mazury, Wojska Polskiego 30, 10-229 Olsztyn, Poland. Tel.: +48 89 6786670; fax: +48 89 6786675.
Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, University of Warmia and Mazury, Wojska Polskiego 30, 10-229 Olsztyn, Poland. Tel.: +48 89 6786670; fax: +48 89 6786675.
Pol. Ann. Med. 2017;24(2):249-255
KEYWORDS
ABSTRACT
Introduction:
Psoriatic patients, especially with psoriatic arthritis (PsA), are more prone to metabolic disorders and involving the eyes.
Aim:
The aim of this study was to present adalimumab efficacy of several aspects of psoriasis and its comorbidities.
Case study:
Wepresent a 48-year-old male patient with severe plaque psoriasis and psoriatic arthritis who developed uveitis with cystoid macular edema in the right eye. The patient was obese although bariatric surgery 8 years earlier produced someweight loss with remission of diabetes and hypertension.
Results and discussion:
The patient had been previously treated with systemic treatment with no improvement in psoriatic arthritis symptoms and skin lesions but rapidly responded to adalimumab. At week 8, the patient achieved the PASI 75, with no joint pain and normal macular architecture. At week 16, there was an incident of atrial fibrillation followed by a transient ischemic attack (TIA). The TIA subsided after intravenous fluids and antithrombotic treatment although acute urticaria developed after the first dose of acetylsalicylic acid. Adalimumab treatment was not stopped and the patient's condition continued to improve.
Conclusions:
After careful consideration of the patient's underlying and comorbid conditions and previous treatment failures, adalimumab was instituted and continued since (1) its efficacy in psoriasis and psoriatic arthritis is well-documented; (2) obesity is not thought to affect its effectiveness; (3) in uveitis adalimumab acts quickly and induces long-term remission; (4) a significant improvement of hemostasis and fibrynolytic balance has been observed in patients on TNF-a inhibitors and adalimumab could be continued after the TIA.
Psoriatic patients, especially with psoriatic arthritis (PsA), are more prone to metabolic disorders and involving the eyes.
Aim:
The aim of this study was to present adalimumab efficacy of several aspects of psoriasis and its comorbidities.
Case study:
Wepresent a 48-year-old male patient with severe plaque psoriasis and psoriatic arthritis who developed uveitis with cystoid macular edema in the right eye. The patient was obese although bariatric surgery 8 years earlier produced someweight loss with remission of diabetes and hypertension.
Results and discussion:
The patient had been previously treated with systemic treatment with no improvement in psoriatic arthritis symptoms and skin lesions but rapidly responded to adalimumab. At week 8, the patient achieved the PASI 75, with no joint pain and normal macular architecture. At week 16, there was an incident of atrial fibrillation followed by a transient ischemic attack (TIA). The TIA subsided after intravenous fluids and antithrombotic treatment although acute urticaria developed after the first dose of acetylsalicylic acid. Adalimumab treatment was not stopped and the patient's condition continued to improve.
Conclusions:
After careful consideration of the patient's underlying and comorbid conditions and previous treatment failures, adalimumab was instituted and continued since (1) its efficacy in psoriasis and psoriatic arthritis is well-documented; (2) obesity is not thought to affect its effectiveness; (3) in uveitis adalimumab acts quickly and induces long-term remission; (4) a significant improvement of hemostasis and fibrynolytic balance has been observed in patients on TNF-a inhibitors and adalimumab could be continued after the TIA.
CONFLICT OF INTEREST
The authors have no conflict of interest.
REFERENCES (36)
1.
Owczarczyk-Saczonek A, Nowicki R. [Psoriasis and comorbidity [29TD$DIF]– literature review]. Wiad Lek. 2014;[30TD$DIF]67:512–519 [in Polish].
2.
Owczarczyk-Saczonek A, Placek W, Wilczek D. [Psoriasis and eyes]. Przegl Dermatol. 2013;100:269–273 [in Polish].
3.
Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67(4):768–773.
4.
Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Dermatology. 2008;217(4):365–373.
5.
Wolk K, Mallbris L, Larsson P, Rosenblad A, Vingård E, Ståhle M. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol. 2009;89(5):492–497.
6.
Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2:e54. http://dx.doi.org/10.1038/nutd....
7.
Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159(4):895–902.
8.
Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71(8):1273–1277.
9.
Bhole VM, Choi HK, Burns LC, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford). 2012;51(3):552–556.
10.
Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012;71(8):1267–1272.
11.
Labitigan M, Bahče-Altuntas A, Kremer JM, et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(4):600–607.
12.
Hossler EW, Wood GC, Still CD, Mowad CM, Maroon MS. The effect of weight loss surgery on the severity of psoriasis. Br J Dermatol. 2013;168(3):660–661.
13.
Faurschou A, Zachariae C, Skov L, Vilsbøll T, Knop FK. Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism? Med Hypotheses. 2011;77(6):1098–1101.
14.
Solis MY, de Melo NS, Macedo ME, et al. Nutritional status and food intake of patients with systemic psoriasis and psoriatic arthritis associated. Einstein (Sao Paulo). 2012;10(1):44–52.
15.
Naldi L, Conti A, Cazzaniga S, et al. Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol. 2014;170(3):634–642.
16.
Au S, Yaniv S, Gottlieb AB. Psoriatic eye manifestations. Psoriasis Forum. 2011;17(3):169–179.
17.
Durrani K, Foster CS. Psoriatic uveitis: a distinct clinical entity? Am J Ophthalmol. 2005;139(1):106–111.
18.
Fraga NA, de Oliveira MF, Follador I, de Rocha BO, Rêgo VR. Psoriasis and uveiti: a literature review. An Bras Dermatol. 2012;87(6):877–883.
19.
Paiva ES, Macaluso DC, Edwards A, Rosenbaum JT. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis. 2000;59(1):67–70.
20.
Parisi R, Rutter MK, Lunt M, et al. Identification and Management of Psoriasis Associated ComorbidiTy (IMPACT) project team. Psoriasis and the risk of major cardiovascular events: cohort study using the Clinical Practice Research Datalink. J Invest Dermatol. 2015;135(9):2189–2197.
21.
Egeberg A, Khalid U, Gislason GH, Mallbris L, Skov L, Hansen PR. Association between depression and risk of atrial fibrillation and stroke in patients with psoriasis: a Danish nationwide cohort study. Br J Dermatol. 2015;173(2):471–479.
22.
Ahlehoff O, Gislason G, Lamberts M, et al. Risk of thromboembolism and fatal stroke in patients with psoriasis and nonvalvular atrial fibrillation: a Danish nationwide cohort study. J Intern Med. 2015;277(4):447–455.
23.
Kimball AB, Guerin A, Latremouille-Viau D, et al. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med. 2010;123(4):350–357.
24.
Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36(6):1115–1119.
25.
Russolillo A, Iervolino S, Peluso R, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford). 2013;52:62–67.
26.
Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2008;22(3):341–344.
27.
Renzo LD, Saraceno R, Schipani C, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-alpha treatment. Dermatol Ther. 2011;24(4):446–451.
28.
Al-Mutairi N, Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert Opin Biol Ther. 2014;14(6):749–756.
29.
Di Minno MN, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor a blockers. Ann Rheum Dis. 2014;73(6):1157–1162.
30.
Lafuente-Urrez RF, Pérez-Pelegay J. Impact of obesity on the effectiveness of adalimumab for the treatment of psoriasis: a retrospective study of 30 patients in daily practice. Eur J Dermatol. 2014;24(2):217–223.
31.
Neri P, Lettieri M, Fortuna C, et al. Adalimumab (HumiraTM in ophthalmology: a review of the literature. Middle East Afr J Ophthalmol. 2010;17(4):290–296.
32.
Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138(4):648–650.
33.
Schaap-Fogler M, Amer R, Friling R, Priel E, Kramer M. Anti-TNF-a agents for refractory cystoid macular edema associated with noninfectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2014;252(4):633–640.
34.
Wang Y, Wang VM, Chan CC. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond). 2011;25(2):127–139.
35.
Di Minno MN, Iervolino S, Peluso R, et al. Hemostatic and fibrinolytic changes are related to inflammatory conditions in patients with psoriatic arthritis – effect of different treatments. J Rheumatol. 2014;41(4):714–722.
36.
Scarpa R, Ayala F, Caporaso N, Olivieri I. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol. 2006;33(2):210–212.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
